| Journal | JAMA |
| Study Type | Randomized Trial |
| Population | Human participants |
This JAMA review synthesizes the current evidence base for therapeutic cannabis use, providing clinicians with a comprehensive assessment of where we have robust data versus areas requiring more research. With over a quarter of North American adults reporting medical cannabis use, understanding the actual evidence quality becomes essential for informed clinical guidance.
This comprehensive review examines therapeutic cannabinoid applications, highlighting FDA-approved indications including HIV/AIDS-related anorexia, chemotherapy-induced nausea and vomiting, and specific pediatric seizure disorders. Meta-analyses demonstrated modest but statistically significant benefits for cannabinoids in reducing nausea and vomiting across various causes (SMD -0.29), with moderate effects on appetite stimulation in HIV/AIDS patients. The review contextualizes these findings against the backdrop of widespread off-label use, with 27% of US/Canadian adults reporting medical cannabis experience and 10.5% using CBD therapeutically.
“This review reinforces what I see clinically—we have solid evidence for a narrow set of conditions, but patients are using cannabis far more broadly than our evidence supports. The modest effect sizes remind me that cannabinoids are therapeutic tools, not miracle cures, requiring the same evidence-based approach as any other medication.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What medical conditions have FDA approval for cannabinoid treatment?
- How effective are cannabinoids for treating nausea and vomiting?
- What’s the difference between CBD and other cannabinoids in terms of psychoactive effects?
- How commonly do people use cannabis for medical purposes?
- Do cannabinoids help with appetite and weight gain in HIV/AIDS patients?
FAQ
What medical conditions have FDA approval for cannabinoid treatment?
The FDA has approved cannabinoids for three specific conditions: HIV/AIDS-related anorexia, chemotherapy-induced nausea and vomiting, and certain pediatric seizure disorders. These represent the most well-established therapeutic uses with rigorous clinical evidence supporting their safety and efficacy.
How effective are cannabinoids for treating nausea and vomiting?
Meta-analysis of randomized clinical trials shows that prescribed cannabinoids like dronabinol and nabilone provide a small but statistically significant reduction in nausea and vomiting compared to placebo or other medications. The standardized mean difference was -0.29, indicating modest but clinically meaningful benefit for patients with chemotherapy-induced or cancer-related nausea.
What’s the difference between CBD and other cannabinoids in terms of psychoactive effects?
CBD (cannabidiol) does not have psychoactive effects, unlike THC-containing cannabinoids. An estimated 10.5% of the US population uses CBD specifically for therapeutic purposes, making it an attractive option for patients seeking medical benefits without the “high” associated with other cannabis compounds.
How commonly do people use cannabis for medical purposes?
Approximately 27% of adults in the US and Canada report having ever used cannabis for medical purposes. Additionally, about 10.5% of the US population specifically uses CBD for therapeutic reasons, indicating widespread interest in cannabinoid-based treatments.
Do cannabinoids help with appetite and weight gain in HIV/AIDS patients?
Meta-analysis of randomized clinical trials in HIV/AIDS patients demonstrates that cannabinoids have a moderate effect on increasing body weight. This finding supports the FDA approval of cannabinoids for HIV/AIDS-related anorexia and provides evidence-based treatment options for this challenging clinical condition.